Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

418461

	registered interest
	date	11/09/2015
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Ehlers-Danlos Syndrome
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what recent assessment he has made of patient outcomes of those diagnosed with Ehlers-Danlos syndrome in (a) London and (b) Greater Manchester.
	tabling member constituency	Bury North
	tabling member printed	Mr David Nuttall
	uin	9987
	answer	answer is ministerial correction date of answer 21/09/2015 answer text <p>Information on patient outcomes of those diagnosed with Ehlers-Danlos Syndrome (EDS) in London and Greater Manchester is not held centrally by the Department. EDS falls within specialised services managed by NHS England.</p><p> </p><p> </p><p> </p><p>The UK Strategy for Rare Diseases sets out the Government’s on-going commitment to ensuring that patients with rare diseases, including EDS, have access to high quality services. The Strategy is discussed regularly with health bodies including NHS England. The national specialised service for atypical or complex cases aims to reduce times to diagnosis and reduce the number of hospital appointments required to achieve a specific diagnosis.</p><p> </p><p> </p><p> </p><p>Information about the average time from diagnosis to referral for specialist treatment is not available centrally. Patients suspected of having EDS may be assessed and diagnosed in a wide range of settings. These include United Kingdom regional clinical genetics clinics and various other secondary and tertiary speciality clinics.</p><p> </p><p> </p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman grouped question UIN 9988 9989 question first answered 21/09/2015 10:00:13 answering member 4020 label Biography information for George Freeman
	tabling member	4140 label Biography information for Mr David Nuttall

418454

	registered interest
	date	11/09/2015
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Ehlers-Danlos Syndrome
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what recent discussions his Department has had with health bodies on ensuring timely treatment for sufferers of Ehlers-Danlos syndrome.
	tabling member constituency	Bury North
	tabling member printed	Mr David Nuttall
	uin	9988
	answer	answer is ministerial correction date of answer 21/09/2015 answer text <p>Information on patient outcomes of those diagnosed with Ehlers-Danlos Syndrome (EDS) in London and Greater Manchester is not held centrally by the Department. EDS falls within specialised services managed by NHS England.</p><p> </p><p> </p><p> </p><p>The UK Strategy for Rare Diseases sets out the Government’s on-going commitment to ensuring that patients with rare diseases, including EDS, have access to high quality services. The Strategy is discussed regularly with health bodies including NHS England. The national specialised service for atypical or complex cases aims to reduce times to diagnosis and reduce the number of hospital appointments required to achieve a specific diagnosis.</p><p> </p><p> </p><p> </p><p>Information about the average time from diagnosis to referral for specialist treatment is not available centrally. Patients suspected of having EDS may be assessed and diagnosed in a wide range of settings. These include United Kingdom regional clinical genetics clinics and various other secondary and tertiary speciality clinics.</p><p> </p><p> </p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman grouped question UIN 9987 9989 question first answered 21/09/2015 10:00:16 answering member 4020 label Biography information for George Freeman
	tabling member	4140 label Biography information for Mr David Nuttall

418457

	registered interest
	date	11/09/2015
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Ehlers-Danlos Syndrome
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what the average length of time is between the diagnosis of a patient with Ehlers-Danlos syndrome and referral for specialist treatment in (a) London and (b) Greater Manchester.
	tabling member constituency	Bury North
	tabling member printed	Mr David Nuttall
	uin	9989
	answer	answer is ministerial correction date of answer 21/09/2015 answer text <p>Information on patient outcomes of those diagnosed with Ehlers-Danlos Syndrome (EDS) in London and Greater Manchester is not held centrally by the Department. EDS falls within specialised services managed by NHS England.</p><p> </p><p> </p><p> </p><p>The UK Strategy for Rare Diseases sets out the Government’s on-going commitment to ensuring that patients with rare diseases, including EDS, have access to high quality services. The Strategy is discussed regularly with health bodies including NHS England. The national specialised service for atypical or complex cases aims to reduce times to diagnosis and reduce the number of hospital appointments required to achieve a specific diagnosis.</p><p> </p><p> </p><p> </p><p>Information about the average time from diagnosis to referral for specialist treatment is not available centrally. Patients suspected of having EDS may be assessed and diagnosed in a wide range of settings. These include United Kingdom regional clinical genetics clinics and various other secondary and tertiary speciality clinics.</p><p> </p><p> </p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman grouped question UIN 9987 9988 question first answered 21/09/2015 10:00:17 answering member 4020 label Biography information for George Freeman
	tabling member	4140 label Biography information for Mr David Nuttall

418262

	registered interest
	date	10/09/2015
	answering body	Ministry of Justice
	answering dept id	54
	answering dept short name	Justice
	answering dept sort name	Justice
	hansard heading	Magistrates' Courts: Bury
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Justice, if his Department has carried out an assessment of the effect of the closure of Bury Magistrates' Court on the (a) cost and (b) duration of journeys between local police stations and the next nearest magistrates' courts.
	tabling member constituency	Bury North
	tabling member printed	Mr David Nuttall
	uin	9877
	answer	answer is ministerial correction date of answer 15/09/2015 answer text <p /> <p>No decision has been taken to close Bury Magistrates’ Court and County Court.</p><p>We will consider all identified impacts and costs once the consultation closes and all responses have been fully analysed.</p> answering member constituency North West Cambridgeshire answering member printed Mr Shailesh Vara grouped question UIN 9878 question first answered 15/09/2015 12:14:46 answering member 1496 label Biography information for Shailesh Vara
	tabling member	4140 label Biography information for Mr David Nuttall

418263

	registered interest
	date	10/09/2015
	answering body	Ministry of Justice
	answering dept id	54
	answering dept short name	Justice
	answering dept sort name	Justice
	hansard heading	Magistrates' Courts: Bury
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Justice, if his Department has carried out an assessment of the effect of the proposed closure of Bury Magistrates' Court on the (a) cost and (b) duration of journeys to the next nearest magistrates' courts for witnesses and victims of crime.
	tabling member constituency	Bury North
	tabling member printed	Mr David Nuttall
	uin	9878
	answer	answer is ministerial correction date of answer 15/09/2015 answer text <p>No decision has been taken to close Bury Magistrates’ Court and County Court.</p><p>We will consider all identified impacts and costs once the consultation closes and all responses have been fully analysed.</p> answering member constituency North West Cambridgeshire answering member printed Mr Shailesh Vara grouped question UIN 9877 question first answered 15/09/2015 12:14:46 answering member 1496 label Biography information for Shailesh Vara
	tabling member	4140 label Biography information for Mr David Nuttall

418256

	registered interest
	date	10/09/2015
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Aspartame
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what research his Department has undertaken or commissioned on possible links between aspartame and (a) aggressive behaviour, (b) depression, (c) anxiety and (d) Graves' Disease.
	tabling member constituency	Bury North
	tabling member printed	Mr David Nuttall
	uin	9849
	answer	answer is ministerial correction date of answer 18/09/2015 answer text <p>We are advised by the Food Standards Agency (FSA) that all food additives, including sweeteners, are only permitted after a robust evaluation of their safety. The foods in which the sweeteners can be used and their conditions of use are regulated under harmonised European Union legislation on food additives.</p><p> </p><p> </p><p> </p><p>The results of an FSA funded study on aspartame were published in March 2015. The study was designed to examine whether self-diagnosed individuals exhibit any reactions which can be observed in a clinical setting, after consuming bars that do or do not contain aspartame. Participants showed no difference in their response whether they contained aspartame or not.</p><p> </p><p> </p><p> </p><p>As part of its systematic re-evaluation of all food additives, the European Food Safety Authority (EFSA) re-evaluated the safety of aspartame and concluded in December 2013 that 'aspartame and its breakdown products are safe for human consumption at current levels of exposure'. In undertaking their re-evaluation EFSA had access to all available, relevant scientific studies and data on aspartame.</p><p> </p><p> </p><p> </p><p>Officials in the FSA have regular discussions with industry, and other interested parties, on a range of issues. Since EFSA reaffirmed the safety on the current use of aspartame, these have not routinely included discussions on aspartame or other sweeteners.</p><p> </p><p> </p><p> </p> answering member constituency Battersea answering member printed Jane Ellison grouped question UIN 9850 9861 9862 question first answered 18/09/2015 09:47:50 answering member 3918 label Biography information for Jane Ellison
	tabling member	4140 label Biography information for Mr David Nuttall

418257

	registered interest
	date	10/09/2015
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Artificial Sweeteners
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what research and discussions his Department has had with the food industry and relevant professional bodies over the safety of aspartame and other artificial sweeteners.
	tabling member constituency	Bury North
	tabling member printed	Mr David Nuttall
	uin	9850
	answer	answer is ministerial correction date of answer 18/09/2015 answer text <p>We are advised by the Food Standards Agency (FSA) that all food additives, including sweeteners, are only permitted after a robust evaluation of their safety. The foods in which the sweeteners can be used and their conditions of use are regulated under harmonised European Union legislation on food additives.</p><p> </p><p> </p><p> </p><p>The results of an FSA funded study on aspartame were published in March 2015. The study was designed to examine whether self-diagnosed individuals exhibit any reactions which can be observed in a clinical setting, after consuming bars that do or do not contain aspartame. Participants showed no difference in their response whether they contained aspartame or not.</p><p> </p><p> </p><p> </p><p>As part of its systematic re-evaluation of all food additives, the European Food Safety Authority (EFSA) re-evaluated the safety of aspartame and concluded in December 2013 that 'aspartame and its breakdown products are safe for human consumption at current levels of exposure'. In undertaking their re-evaluation EFSA had access to all available, relevant scientific studies and data on aspartame.</p><p> </p><p> </p><p> </p><p>Officials in the FSA have regular discussions with industry, and other interested parties, on a range of issues. Since EFSA reaffirmed the safety on the current use of aspartame, these have not routinely included discussions on aspartame or other sweeteners.</p><p> </p><p> </p><p> </p> answering member constituency Battersea answering member printed Jane Ellison grouped question UIN 9849 9861 9862 question first answered 18/09/2015 09:47:50 answering member 3918 label Biography information for Jane Ellison
	tabling member	4140 label Biography information for Mr David Nuttall

418258

	registered interest
	date	10/09/2015
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Artificial Sweeteners
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what recent discussions his Department has had with the food industry and relevant professional bodies on the safety of (a) aspartame and (b) other artificial sweeteners.
	tabling member constituency	Bury North
	tabling member printed	Mr David Nuttall
	uin	9861
	answer	answer is ministerial correction date of answer 18/09/2015 answer text <p>We are advised by the Food Standards Agency (FSA) that all food additives, including sweeteners, are only permitted after a robust evaluation of their safety. The foods in which the sweeteners can be used and their conditions of use are regulated under harmonised European Union legislation on food additives.</p><p> </p><p> </p><p> </p><p>The results of an FSA funded study on aspartame were published in March 2015. The study was designed to examine whether self-diagnosed individuals exhibit any reactions which can be observed in a clinical setting, after consuming bars that do or do not contain aspartame. Participants showed no difference in their response whether they contained aspartame or not.</p><p> </p><p> </p><p> </p><p>As part of its systematic re-evaluation of all food additives, the European Food Safety Authority (EFSA) re-evaluated the safety of aspartame and concluded in December 2013 that 'aspartame and its breakdown products are safe for human consumption at current levels of exposure'. In undertaking their re-evaluation EFSA had access to all available, relevant scientific studies and data on aspartame.</p><p> </p><p> </p><p> </p><p>Officials in the FSA have regular discussions with industry, and other interested parties, on a range of issues. Since EFSA reaffirmed the safety on the current use of aspartame, these have not routinely included discussions on aspartame or other sweeteners.</p><p> </p><p> </p><p> </p> answering member constituency Battersea answering member printed Jane Ellison grouped question UIN 9849 9850 9862 question first answered 18/09/2015 09:47:50 answering member 3918 label Biography information for Jane Ellison
	tabling member	4140 label Biography information for Mr David Nuttall

418259

	registered interest
	date	10/09/2015
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Aspartame
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what recent assessment his Department has made of the safety of aspartame in food and other consumable products.
	tabling member constituency	Bury North
	tabling member printed	Mr David Nuttall
	uin	9862
	answer	answer is ministerial correction date of answer 18/09/2015 answer text <p>We are advised by the Food Standards Agency (FSA) that all food additives, including sweeteners, are only permitted after a robust evaluation of their safety. The foods in which the sweeteners can be used and their conditions of use are regulated under harmonised European Union legislation on food additives.</p><p> </p><p> </p><p> </p><p>The results of an FSA funded study on aspartame were published in March 2015. The study was designed to examine whether self-diagnosed individuals exhibit any reactions which can be observed in a clinical setting, after consuming bars that do or do not contain aspartame. Participants showed no difference in their response whether they contained aspartame or not.</p><p> </p><p> </p><p> </p><p>As part of its systematic re-evaluation of all food additives, the European Food Safety Authority (EFSA) re-evaluated the safety of aspartame and concluded in December 2013 that 'aspartame and its breakdown products are safe for human consumption at current levels of exposure'. In undertaking their re-evaluation EFSA had access to all available, relevant scientific studies and data on aspartame.</p><p> </p><p> </p><p> </p><p>Officials in the FSA have regular discussions with industry, and other interested parties, on a range of issues. Since EFSA reaffirmed the safety on the current use of aspartame, these have not routinely included discussions on aspartame or other sweeteners.</p><p> </p><p> </p><p> </p> answering member constituency Battersea answering member printed Jane Ellison grouped question UIN 9849 9850 9861 question first answered 18/09/2015 09:47:50 answering member 3918 label Biography information for Jane Ellison
	tabling member	4140 label Biography information for Mr David Nuttall

417802

	registered interest
	date	08/09/2015
	answering body	Wales Office
	answering dept id	28
	answering dept short name	Wales
	answering dept sort name	Wales
	hansard heading	Wales Office: UK Membership of EU
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Wales, how many officials in his Department are engaged in research into the effects of the UK leaving the EU.
	tabling member constituency	Bury North
	tabling member printed	Mr David Nuttall
	uin	9511
	answer	answer is ministerial correction date of answer 14/09/2015 answer text <p>The Government is focused on delivering a successful renegotiation: it believes it can and will succeed in reforming and renegotiating our relationship with the EU and campaigning to keep the UK in the EU on that basis. Departments are appropriately resourced to support the Government’s priorities in Europe. Ministers and officials regularly meet with a range of external organisations to discuss the Government's objectives in Europe. Details of Ministerial meetings with external organisations are published quarterly.</p><p> </p> answering member constituency Preseli Pembrokeshire answering member printed Stephen Crabb grouped question UIN 9529 9548 question first answered 14/09/2015 14:28:47 answering member 1554 label Biography information for Stephen Crabb
	tabling member	4140 label Biography information for Mr David Nuttall